Researchers have identified a technique to determining which patients with a genetic mutation that cause long QT Syndrome type 3 will benefit from mexiletine.
Read more via theSource and Circulation Research.
Get your free access to the exclusive newsletter of American Nurse Journal and gain insights for your nursing practice.
NurseLine Newsletter
*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.
